Results 131 to 140 of about 2,872,365 (306)

Chronic Kidney Disease‐Associated Pruritus Is Linked to Selective Enrichment of Taurine‐Conjugated Bile Acid Subspecies

JEADV Clinical Practice, EarlyView.
Chronic kidney disease‐associated pruritus (CKDaP) is a frequent complication of advanced CKD with an incompletely understood pathophysiology. We identified a significantly altered glycine‐to‐taurine conjugated bile acid ratio in patients with CKDaP despite unchanged total serum bile acid concentrations.
Miriam M. Düll, Manfred Rauh, Peter Dietrich, Marcel Vetter, Jonas Schmid, Thomas Mettang, Andreas E. Kremer   +6 more
wiley   +1 more source

Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions

Indian Journal of Psychiatry, 2018
The most evidence-based treatment for opioid dependence is opioid agonist maintenance treatment also known as opioid substitution therapy (OST). However, there are some critical, yet unaddressed issues of buprenorphine-based substitution therapy ...
Abhishek Ghosh, Debasish Basu, Ajit Avasthi   +2 more
doaj   +1 more source

Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy.

Clinical Infectious Diseases, 2019
BACKGROUND This study investigated treatment adherence and associated factors among people with recent injecting drug use or current opioid agonist therapy (OAT) and compared once-daily to twice-daily DAA therapy.
E. Cunningham, Behzad Hajarizadeh, J. Amin, A. Litwin, Edward J. Gane, C. Cooper, K. Lacombe, M. Hellard, Phillip Read, J. Powis, O. Dalgard, Julie Bruneau, G. Matthews, Jordan J. Feld, J. Dillon, David Shaw, P. Bruggmann, Brian Conway, C. Fraser, P. Marks, Gregory J. Dore, J. Grebely   +21 more
semanticscholar   +1 more source

Barriers and facilitators to office-based opioid agonist therapy prescribing and effective interventions to increase provider prescribing: protocol for a systematic review

Systematic Reviews, 2019
Background Opiate agonist therapy (OAT) prescribing rates by family physicians are low in the context of community-based, comprehensive primary care. Understanding the factors that support and/or inhibit OAT prescribing within primary care is needed. Our
Lara L. Nixon, Jazmin C. Marlinga, K. Alix Hayden, Kelly J. Mrklas   +3 more
doaj   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study

Movement Disorders, EarlyView.
Abstract Background Pain is a common non‐motor symptom in Parkinson’s disease (PD) and is often associated to fluctuations. Objective The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) study evaluated the effect of opicapone on fluctuation‐related pain when added to levodopa therapy in PD patients.
Kallol Ray Chaudhuri, Joaquim J. Ferreira, Angelo Antonini, Olivier Rascol, Monica M. Kurtis, Alexander Storch, José‐Francisco Rocha, Raquel Costa, Diogo Magalhães, Guillermo Castilla‐Fernández, Helena C. Brigas, Joerg Holenz, Per Odin, on behalf of the OCEAN study group   +13 more
wiley   +1 more source

Cross‐Cohort Evidence Links KCNJ6 rs702859 to Impulsive–Compulsive Phenotypes in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Impulse control disorders (ICDs) and related compulsive behaviors (CBs) are frequent non‐motor complications of Parkinson's disease (PD) with a probable genetic contribution. Objective To investigate whether genetic variants involved in reward and punishment processing are associated with impulsive–compulsive phenotypes in PD ...
Sergio García‐Díaz, Juan Francisco Martín‐Rodríguez, Laura Muñoz‐Delgado, Rafael Díaz‐Belloso, Silvia Jesús, María Teresa Periñán, Miguel Martín‐Bórnez, Ana M. Castellano‐Guerrero, Elena Ojeda‐Lepe, Daniel Macías‐García, Astrid Adarmes‐Gómez, Dolores Buiza‐Rueda, Marta Bonilla‐Toribio, Elena Iglesias‐Camacho, Manuela San‐Eufrasio, Cristina Pérez‐Calvo, Rocío Pineda‐Sánchez, Francisco Javier Gómez‐Campos, Antonio Luque‐Ambrosiani, Fátima Carrillo‐García, Pilar Gómez‐Garre, Pablo Mir   +21 more
wiley   +1 more source

Safety of opioid patch initiation in Australian residential aged care [PDF]

, 2015
Explores opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Abstract Objective: To explore opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Design:
Lisa Pont, Svetla Gadzhanova, Elizabeth Roughead, Roughead, E.E., Pont, L.G., Gadzhanova, S.   +5 more
core   +1 more source

Developing the Dopamine D3 Receptor (D3R) Antagonist, (R)‐VK4‐116, as a Non‐Opioid Medication for the Treatment of Opioid Use Disorder

Medicinal Research Reviews, EarlyView.
ABSTRACT Opioid use disorder (OUD) remains a major global health challenge, and currently approved treatments (methadone, buprenorphine, and naltrexone) are all opioid receptor‐targeting drugs with limitations in access, adherence, stigma, and use in polysubstance use disorders. Because the dopamine D3 receptor (D3R) is enriched in limbic brain regions
Chia‐Kuei Wu, Yu‐Chih Lin, Junfeng Huang, Bangwei Ding, Pramod Terse, Rahul Nandre, Haksong Jin, Molly Congdon, Kun Shen, Philip Sanderson, Gregory Tawa, Stephanie Mounaud, Marta De Santis, Donald Lo, Elizabeth A. Ottinger, Amy Hauck Newman   +15 more
wiley   +1 more source

Biological evaluation and molecular docking studies of AA3052, a compound containing a μ-selective opioid peptide agonist DALDA and D-Phe-Phe-D-Phe-Leu-Leu-NH2, a substance P analogue [PDF]

, 2016
The design of novel drugs for pain reliefwith improved analgesic properties and diminished side effect induction profile still remains a challenging pursuit.
Martin Charlotte, Bujalska-Zadrozny Magdalena, Rękawek, Monika, Kleczkowska, Patrycja, Kowalczyk Agnieszka, Lesniak Anna, Lesniak, Anna, Borics, Attila, Rękawek Monika, Makulska-Nowak Helena, Kowalczyk, Agnieszka, Kleczkowska Patrycja, Pawlik, Karolina, Erdei, Anna, Benyhe Sándor, Lipkowski, Andrzej W., Makulska-Nowak, Helena, Borics Attila, Kulik Kamila, Lipkowski Andrzej W., Benyhe, Sándor, Ballet, Steven, Martin, Charlotte, Kulik, Kamila, Pawlik Karolina, Bujalska-Zadrozny, Magdalena, Erdei Anna, Ballet Steven   +27 more
core   +1 more source